Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843360 | 1.00 | GLS (0.40) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21797357 | 1.00 | GLS (0.40) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21738019 | 1.00 | GLS (0.40) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21738050 | 0.95 | GLS (0.41) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21797680 | 0.95 | GLS (0.41) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21738014 | 0.95 | GLS (0.41) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21797678 | 0.95 | GLS (0.41) | GLSMEN1POLBKMT2AMAPT | |
| SCHEMBL21738234 | 0.89 | GLS (0.39) | GLSMEN1POLBKMT2AACACB | |
| SCHEMBL21738025 | 0.89 | GLS (0.39) | GLSMEN1POLBKMT2AACACB | |
| SCHEMBL21725085 | 0.87 | GLS (0.38) | GLSACACBALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | GLS 2363/4885MEN1 2537/4885POLB 2429/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | GLS 2423/4885MEN1 2601/4885POLB 2413/4885 |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | GLS 2423/4885MEN1 2601/4885POLB 2413/4885 |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | IRAK4, IRAK3, IRAK2 | GLS 2363/4885MEN1 2537/4885POLB 2429/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | GLS 2423/4885MEN1 2601/4885POLB 2413/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | GLS 2423/4885MEN1 2601/4885POLB 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.